Conference 2015

Meningitis and Septicaaemia in Children and Adults 2015

Wednesday 4 and Thursday 5 November 2015

Royal Society of Medicine, 1 Wimpole Street, London W1G 0AE London UK

Our tenth conference will bring together internationally renowned experts from a range of specialties in the UK and abroad to address the most important issues of the day, including burden of illness, recognition and treatment, vaccine development, vaccine implementation and public health policy.

Attracting delegates from around the world, this conference is a key event in the calendar for some of the foremost scientists and clinicians and provides an excellent opportunity to discuss the latest developments within the field.

Confirmed speakers:
  • Dr Mark Alderson, Director, PATH Pneumococcal Vaccine Project on future prospects for preventing pneumococcal infection
  • Dr Nicole Basta, Assistant Professor, Division of Epidemiology and Community Health, School of Public Health, University of Minnesota on meningococcal B outbreaks in US universities
  • Professor Ray Borrow, Head of the Vaccine Evaluation Unit, Public Health England, Manchester on plans for enhanced surveillance and evaluation of efficacy of Bexsero
  • Professor Philippe De Wals, Professor of Social and Preventive Medicine, Laval University, Quebec City, Canada on the use of Bexsero in Quebec
  • Professor Sir Brian Greenwood, Professor of Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine on an overview of the MenAfriCar project
  • Professor Rob Heyderman, Professor of of Infectious Diseases and International Health
    UCL on epidemics of Non-typhoidal Salmonella sepsis and meningitis in Africa
  • Dr Jay Lucidarme, Healthcare Scientist Practitioner, Vaccine Evaluation Unit, Public Health England, Manchester on the first use of genomics to inform national meningococcal immunisation policy
  • Professor Martin Maiden, Professor of Molecular Epidemiology, University of Oxford UK on UK meningococcal ACWY and B carriage studies and realisation of genome sequencing
  • Dr Fiona McGill,  University of Liverpool on adult bacterial meningitis & meningococcal sepsis guidelines
  • Professor Elizabeth Miller, Consultant Epidemiologist, Public Health England, London on impact of 13V pneumococcal vaccine on invasive pneumococcal disease and meningitis in the UK
  • Prof Xavier Nassif,  INSERM Paris on vascular colonisation by meningococcal bacteria
  • Dr Ifeanyichukwu Okike, Derby Children’s Hospital on Clinical care of neonatal meningitis in the UK
  • Dr Marie-Pierre Preziosi, Medical Officer, Initiative for Vaccine Research, Department of Immunization, Vaccines and Biologicals, World Health Organization on the impact of MenAfriVac in the Meningitis Belt and prospects for meningococcal disease prevention through EPI and higher valent vaccines
  • Dr Mary Ramsay, Head of Immunisation, Public Health England on Introduction of Bexsero and MenACWY in the UK
  • Dr Olivier Ronveaux, WHO meningitis team, Geneva on current epidemiology of meningococcal disease in the Meningitis Belt and new WHO outbreak response guidelines after the Meningitis Vaccine Project
  • Dr Marco Safadi, Pediatric Division Head, FCM da Santa Casa de São Paulo on the South American experience; control measures and impact
Steering committee:
  • Professor Ray Borrow, Public Health England
  • Professor Ian Feavers, National Institute for Biological Standards and Control
  • Professor Adam Finn, University of Bristol
  • Professor Brian Greenwood, London School of Hygiene and Tropical Medicine
  • Professor George Griffin, St George’s University London
  • Professor Paul Heath, St George’s University London
  • Professor Rob Heyderman, University College London
  • Professor Nigel Klein, Great Ormond Street/University College London
  • Professor David Lalloo, Liverpool School of Tropical Medicine
  • Dr Simon Nadel, St Mary’s Hospital / Imperial College London
  • Dr Mary Ramsay, Public Health England
  • Professor Christoph Tang, University of Oxford
  • Dr Caroline Trotter, University of Cambridge
  • Linda Glennie, Meningitis Research Foundation

Call for poster abstracts for Meningitis and Septicaemia in Children and Adults 2015

Conference sponsorship opportunities

Delegate fees:

Standard non-commercial  rate

early booking discount before 7 September

One day - £140- Book online with your credit or debit card
Both days - £220 - Book online with your credit or debit card

Commercial  rate

One day - £260 - Book online with your credit or debit card
Both days - £350 - Book online with your credit or debit card

Discounted fees for junior trainees, nurses and post-docs

One day - £110 - Book online with your credit or debit card
Both days - £175 -Book online with your credit or debit card

If you prefer, you can use our downloadable booking form:

For more information, to book over the phone or to raise a booking invoice to pay against, please email Paul George or call him on +44 (0)1454 281811

Meningitis and Septicaemia in Children and Adults 2015's major sponsors are:



Novartis Vaccines' non-influenza business has now transferred to GSK

The conference is also supported by: